Sign in
CompletedNo phase

Effect of Different Frequencies of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD

Key facts

Who runs it
General Hospital of Shenyang Military Region
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
92 people enrolled
Started
5 Mar 2024
Ended
30 Dec 2025
Type of study
Interventional, 2 groups
Treatments tested
  • umbilical cord-mesenchymal stem cells
Record updated
31 March 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • 1. 18-80 years old
  • 2. End-stage liver disease
  • 3. Signed informed consent

Who cannot take part

  • 2. Liver transplantation recipients
  • 6. Interferon or glucocorticoid therapy within 1 year
  • 3. Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases
  • 4. Other diseases that may seriously affect the survival
  • 5. Human immunodeficiency syndrome
  • 7. Treated for mental illness
  • 10. Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies
  • 1. Tumours of the liver or other organs
  • 8. Participation in other clinical trials within 30 days
  • 9. Pregnant or breastfeeding subjects
  • 11. Other circumstances that are unsuitable for participation in this study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury. Randomized controlled trials have confirmed the efficacy of single infusion of stem cells in treating ESLD. It seems that the multiple infusion is better than single infusion.

The 2 groups in the trial

  • Single-infusion groupTreatment being tested

    Single peripheral venous infusion of stem cells

    Treatment: umbilical cord-mesenchymal stem cells

  • Double-infusion groupTreatment being tested

    Repeated peripheral venous infusion of stem cells within one month

    Treatment: umbilical cord-mesenchymal stem cells

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Different Frequencies of Human Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With End-stage Liver Disease
Record updated
31 March 2026